HUMA Relative Valuation
HUMA's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, HUMA is overvalued; if below, it's undervalued.
Historical Valuation
Humacyte Inc (HUMA) is now in the Undervalued zone, suggesting that its current forward PS ratio of 31.51 is considered Undervalued compared with the five-year average of -6.09. The fair price of Humacyte Inc (HUMA) is between 3.07 to 7.61 according to relative valuation methord. Compared to the current price of 2.36 USD , Humacyte Inc is Undervalued By 23.03%.
Relative Value
Fair Zone
3.07-7.61
Current Price：2.36
23.03%
Undervalued
Trailing
Forward
P/E
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
11.02
P/B
Median3y
2.39
Median5y
2.76
-25.09
FCF Yield
Median3y
-21.61
Median5y
-19.31
Competitors Valuation Multiple
The average P/S ratio for HUMA's competitors is 22.54, providing a benchmark for relative valuation. Humacyte Inc Corp (HUMA) exhibits a P/S ratio of 31.51, which is 39.81% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
People Also Watch
FAQ
Is Humacyte Inc (HUMA) currently overvalued or undervalued?
What is Humacyte Inc (HUMA) fair value?
How does HUMA's valuation metrics compare to the industry average?
What is the current P/B ratio for Humacyte Inc (HUMA) as of Jun 20 2025?
What is the current FCF Yield for Humacyte Inc (HUMA) as of Jun 20 2025?
What is the current Forward P/E ratio for Humacyte Inc (HUMA) as of Jun 20 2025?